Nichelle C Whitlock
Overview
Explore the profile of Nichelle C Whitlock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilkinson S, Ku A, Lis R, King I, Low D, Trostel S, et al.
medRxiv
. 2024 Feb;
PMID: 38370835
Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition to...
2.
Whitlock N, White M, Capaldo B, Ku A, Agarwal S, Fang L, et al.
Discov Oncol
. 2022 Oct;
13(1):97.
PMID: 36181613
Background: The activities of MYC, the androgen receptor, and its associated pioneer factors demonstrate substantial reprogramming between early and advanced prostate cancer. Although previous studies have shown a shift in...
3.
Sowalsky A, Figueiredo I, Lis R, Coleman I, Gurel B, Bogdan D, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3509-3525.
PMID: 35695870
Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical...
4.
Bright J, Lis R, Ku A, Terrigino N, Whitlock N, Trostel S, et al.
J Urol
. 2022 Mar;
208(1):90-99.
PMID: 35227084
Purpose: Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of...
5.
Morel K, Sheahan A, Burkhart D, Baca S, Boufaied N, Liu Y, et al.
Nat Cancer
. 2021 Apr;
2(4):444-456.
PMID: 33899001
Prostate cancers are considered to be immunologically 'cold' tumors given the very few patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of interferon-stimulated genes (ISGs) predicted a favorable...
6.
Wilkinson S, Ye H, Karzai F, Harmon S, Terrigino N, VanderWeele D, et al.
Eur Urol
. 2021 Mar;
80(6):746-757.
PMID: 33785256
Background: Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients...
7.
Sharad S, Allemang T, Li H, Nousome D, Ku A, Whitlock N, et al.
Front Oncol
. 2021 Feb;
10:584280.
PMID: 33575208
Prostate cancer incidence in young men has increased. Patients diagnosed at an earlier age are likely to have aggressive prostate cancer and treatment decisions are continuing to be weighted by...
8.
Whitlock N, Trostel S, Wilkinson S, Terrigino N, Hennigan S, Lake R, et al.
Oncogene
. 2020 Jul;
39(34):5663-5674.
PMID: 32681068
Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst the most well-characterized drivers of prostate tumorigenesis. Canonically, MYC up-regulation in...
9.
Hennigan S, Trostel S, Terrigino N, Voznesensky O, Schaefer R, Whitlock N, et al.
JCO Precis Oncol
. 2019 Sep;
3.
PMID: 31528835
Purpose: Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies for detection of clinically significant disease before treatment....
10.
Whitlock N, Baek S
Nutr Cancer
. 2012 Apr;
64(4):493-502.
PMID: 22482424
Resveratrol (3, 4', 5-trihydroxystilbene), a naturally occurring phytoalexin readily available in the diet, is reported to possess both chemopreventive and chemotherapeutic activities in several cancers. However, despite the identification of...